# US 2024/0200065 A1 · Compositions and methods useful for the treatment of h-abc leukodystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200065 A1
- Document ID: US20240200065A1
- Status: Published application
- Kind: A1
- Application number: 18/287,150
- Filed: 2022-04-18
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Adeline VANDERVER; Sunetra SASE; Akshata ALMAD
- Web page: https://patentgrep.com/patent/US20240200065A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2330/31: Libraries, arrays
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for the treatment of H-ABC leukodystrophy are disclosed.

## Claims

### Claim 1

A method of lowering TUBB4A levels in targeted cells, thereby improving symptoms of H-ABC leukodystrophy in a patient in need thereof, the method comprising administration of a therapeutically effective amount of a composition comprising a synthetic inhibitory nucleic acid molecule targeting TUBB4A, wherein lowering TUBB4A levels in said cell and reducing one or more of
i) delayed motor development;
ii) cognitive dysfunction;
iii) gait dysfunction;
iv) ataxia;
v) intention tremor;
vi) dysarthria;
vii) dysphonia; and
viii) aberrant hypomyelination;
in said patient, wherein the synthetic nucleic acid molecule is selected from an antisense oligonucleotide, an shRNA, an siRNA, and a guide strand suitable for CRISPR editing TUBB4A targeted nucleic acids.

### Claim 2

A method of treating, delaying the onset of, ameliorating, and/or reducing a disease, disorder and/or condition, or a symptom thereof, associated with H-ABC leukodystrophy in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a synthetic nucleic acid targeting TUBB4A, wherein the disease, disorder and/or condition, or the symptom thereof, associated with H-ABC leukodystrophy is treated, inhibited, the onset delayed, ameliorated, and/or reduced in the patient, wherein the synthetic nucleic acid molecule is selected from an antisense oligonucleotide, an shRNA, an siRNA, and a guide strand suitable for CRISPR editing.

### Claim 3 (depends on 1)

The method of claim 1, wherein said synthetic nucleic acid targeting TUBB4A is modified to increase stability and/or uptake in vivo.

### Claim 4 (depends on 1)

The method of claim 1, wherein said synthetic nucleic acid targeting TUBB4A is a modified antisense oligonucleotide.

### Claim 5 (depends on 1)

The method of claim 1, wherein said synthetic nucleic acid encoding said antisense oligonucleotide is cloned into a vector.

### Claim 6 (depends on 5)

The method of claim 5, wherein said vector is selected from a plasmid vector, a lentiviral vector, a retroviral vector, an AAV vector, and an adenovirus associated vector.

### Claim 7

The method of 6, wherein the disease, disorder and/or condition is associated with hypomyelination.

### Claim 8 (depends on 4)

The method of claim 4, where said synthetic nucleic acid is an antisense oligonucleotide provided in Table 3 or Table 5.

### Claim 9 (depends on 8)

The method of claim 8, wherein the nucleic acid is modified and has a nucleobase sequence that is at least 90%, at least 95%, at least 99%, or 100% complementary to a portion of a human TUBB4A nucleic acid.

### Claim 10 (depends on 9)

The method of claim 9, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one nucleoside of the modified oligonucleotide comprises a modified sugar or at least one nucleoside of the modified oligonucleotide comprises a modified nucleobase.

### Claim 11 (depends on 1)

The method of claim 1, further comprising an additional active pharmaceutical agent useful for treatment of leukodystrophy.

### Claim 12

A composition for reducing expression of TUBB4A, comprising a synthetic nucleic acid molecule targeting, and specifically hybridizing to, a TUBB4A encoding nucleic acid, selected from an antisense oligonucleotide, an shRNA, an siRNA, and a guide strand suitable for CRISPR editing in a biologically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12, wherein said synthetic nucleic acid is modified to increase stability in bodily fluids and/or uptake in a cell of interest.

### Claim 14 (depends on 12)

The composition of claim 12, wherein said synthetic nucleic acid is listed in Table 3 or Table 5.

### Claim 15

The composition of 12, wherein said synthetic nucleic acid molecule is present in a vector.

### Claim 16 (depends on 12)

The composition according to claim 12, formulated for ex vivo cellular administration, intracranial administration, parenteral administration, and intravenous administration.

### Claim 17

The composition of 12 formulated for single intracerebroventricular (ICV) bolus injection.

### Claim 18 (depends on 1)

A kit comprising for practicing the methods of claim 1.

### Claim 19 (depends on 12)

The composition of claim 12, wherein said synthetic nucleic acid is ASO H14 or ASO H15.

### Claim 20 (depends on 19)

The composition of claim 19, wherein said synthetic nucleic is present in vector selected from a plasmid vector, a lentiviral vector, a retroviral vector, an AAV vector, and an adenovirus associated vector, and is formulated for a route of administration selected from ex vivo cellular administration, intracranial administration, parenteral administration, intravenous administration, and single intracerebroventricular (ICV) bolus injection.
